HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	LY2780301 Sensitive: C2 – Inclusion Criteria LY2780301 Sensitive : C2	LY2780301 Sensitive: C2 – Inclusion Criteria LY2780301 Sensitive : C2
ER positive + ESR1 mutation	HER2 Negative Breast Cancer	ER positive + ESR1 mutation	HER2 Negative Breast Cancer	DIACC3010 Sensitive: C3 – Early Trials DIACC3010 Sensitive : C3	DIACC3010 Sensitive: C3 – Early Trials DIACC3010 Sensitive : C3
AKT1 E17K + HR positive	HER2 Negative Breast Cancer	AKT1 E17K + HR positive	HER2 Negative Breast Cancer	DIACC3010 Sensitive: C4 – Case Studies DIACC3010 Sensitive : C4	DIACC3010 Sensitive: C4 – Case Studies DIACC3010 Sensitive : C4
PIK3CA H1047R + HER-2 amplification	Breast Cancer	PIK3CA H1047R + HER-2 amplification	Breast Cancer	trastuzumab + DIACC3010 Sensitive: C4 – Case Studies trastuzumab + DIACC3010 Sensitive : C4	trastuzumab + DIACC3010 Sensitive: C4 – Case Studies trastuzumab + DIACC3010 Sensitive : C4
AKT2 expression	B Acute Lymphoblastic Leukemia	AKT2 expression	B Acute Lymphoblastic Leukemia	CCT128930 Sensitive: D – Preclinical CCT128930 Sensitive : D	CCT128930 Sensitive: D – Preclinical CCT128930 Sensitive : D
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	CCT128930 Sensitive: D – Preclinical CCT128930 Sensitive : D	CCT128930 Sensitive: D – Preclinical CCT128930 Sensitive : D
HER-2 negative	Gastric Cancer	HER-2 negative	Gastric Cancer	trastuzumab + DIACC3010 Sensitive: D – Preclinical trastuzumab + DIACC3010 Sensitive : D	trastuzumab + DIACC3010 Sensitive: D – Preclinical trastuzumab + DIACC3010 Sensitive : D
HER-2 negative	Gastric Cancer	HER-2 negative	Gastric Cancer	DIACC3010 Sensitive: D – Preclinical DIACC3010 Sensitive : D	DIACC3010 Sensitive: D – Preclinical DIACC3010 Sensitive : D

p70S6K inhibitor

p70S6K inhibitor

Associations(8)

Associations
(8)